◆英語タイトル:Epigenomics AG (ECX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10104
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi proLung, a validating test for the diagnosis of lung cancer. The company’s molecular diagnostic products are based on its proprietary methylation technology, which is based on biological phenomenon called DNA methylation. Epigenomics’ pipeline also comprises tests for monitoring, screening, diagnosis and prognosis assessment of colorectal and lung cancer. It also offers services such as basic research, product development, validate DNA methylation (epigenetic) biomarkers and support for obtaining regulatory approvals. Epigenomics is headquartered in Berlin, Germany.
Epigenomics AG (ECX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Epigenomics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Epigenomics AG, Medical Devices Deals, 2012 to YTD 2018 9
Epigenomics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Epigenomics AG, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 11
Equity Offering 12
Epigenomics Raises USD25.71 Million in Rights Offering of Shares 12
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 14
Debt Offering 15
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 15
Epigenomics AG – Key Competitors 16
Epigenomics AG – Key Employees 17
Epigenomics AG – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Financial Announcements 19
Aug 08, 2018: Epigenomics Announces 2018 Second Quarter and Six Month Financial Results 19
May 09, 2018: Epigenomics announces 2018 First Quarter Financial Results 20
Mar 23, 2018: Epigenomics Reports Results for Financial Year 2017 21
Nov 15, 2017: Epigenomics Announces 2017 Third Quarter and Nine Months Financial Results 23
Aug 09, 2017: Epigenomics Announces 2017 Second Quarter and Six Months Financial Results 24
Corporate Communications 25
Nov 29, 2017: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive VP Finance and a Member of the Management Board (Vorstand) 25
Nov 05, 2017: Supervisory Board of Epigenomics Appoints Dr. Jorge Garces as President and Chief Scientific Officer 26
Other Significant Developments 27
Jul 25, 2018: Launch of Single Cell Accelerator drives VIB to forefront of single cell research 27
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List of Tables
Epigenomics AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Epigenomics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Epigenomics AG, Deals By Therapy Area, 2012 to YTD 2018 8
Epigenomics AG, Medical Devices Deals, 2012 to YTD 2018 9
Epigenomics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Epigenomics And Wuhan Kindstar Enter Into Licensing Agreement For Epi Prolung 11
Epigenomics Raises USD25.71 Million in Rights Offering of Shares 12
Epigenomics Files Draft Registration Statement for US Public Offering of Shares 14
Epigenomics Raises USD8.5 Million in Private Placement of Bonds 15
Epigenomics AG, Key Competitors 16
Epigenomics AG, Key Employees 17
Epigenomics AG, Subsidiaries 18
List of Figures
Epigenomics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Epigenomics AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Epigenomics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Epigenomics AG, Medical Devices Deals, 2012 to YTD 2018 9